These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10528431)

  • 1. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
    Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
    Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
    Greco C; Alvino S; Del Monte G; Venturo I; Lopez M
    J Exp Clin Cancer Res; 2003 Dec; 22(4):607-12. PubMed ID: 15053303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
    Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
    Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
    Bataille R; Jourdan M; Zhang XG; Klein B
    J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
    Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
    Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
    Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
    Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
    Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
    Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
    Mayo MM; Johns GS
    Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Positive expression of c-myc and p53 products in two cases of pulmonary sclerosing hemangioma].
    Chiba W; Sawai S; Yasuda Y; Wazawa H; Matsubara Y; Ikeda S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec; 33(12):1348-54. PubMed ID: 8821986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of C-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions.
    Greco C; Gandolfo GM; Mattei F; Gradilone A; Alvino S; Pastore LI; Casale V; Casole P; Grassi A; Cianciulli AM
    Anticancer Res; 1994; 14(3B):1433-40. PubMed ID: 8067719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of serum interleukin-6 concentration by an enzyme-linked immunosorbent assay in patients with paraproteinemia].
    Yamagishi Y; Hidaka Y; Sasaki K; Nihei K; Itoh Y; Kawai T
    Rinsho Byori; 1992 Mar; 40(3):303-10. PubMed ID: 1518181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-MYB, serum P-53M, genetic instability, labeling index and endoscopic findings in patients with adenoma or colorectal cancer.
    Assisi D; Grassi A; La Penta R; Stigliano V; Greco C; Cianciulli AM; Giannarelli D; Casale V
    J Exp Clin Cancer Res; 2004 Sep; 23(3):469-75. PubMed ID: 15595638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
    Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
    Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
    Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
    Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
    IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathies with a high MC elicit altered phenotypic and genotypic features.
    Greco C; Alvino S; Mosiello A; Avilii G; Mattei F; Francavilla V; Valente F; Del Monte G; Cianciulli AM; Gandolfo GM
    Eur J Histochem; 1997; 41 Suppl 2():19-20. PubMed ID: 9859764
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral SPARC/osteonectin protein in plasma cell dyscrasias.
    Turk N; Kusec R; Jaksic B; Turk Z
    Ann Hematol; 2005 May; 84(5):304-10. PubMed ID: 15645230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.